MARKET

DNLI

DNLI

Denali Therapeut
NASDAQ
20.11
+1.11
+5.84%
Pre Market: 20.11 0 0.00% 08:09 12/05 EST
OPEN
18.77
PREV CLOSE
19.00
HIGH
20.49
LOW
18.47
VOLUME
795
TURNOVER
0
52 WEEK HIGH
26.18
52 WEEK LOW
10.57
MARKET CAP
2.95B
P/E (TTM)
-6.9083
1D
5D
1M
3M
1Y
5Y
1D
Denali Therapeutics price target raised to $31 from $30 at Wedbush
TipRanks · 1h ago
Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus
TipRanks · 1h ago
DENALI THERAPEUTICS INC <DNLI.O>: WEDBUSH RAISES TARGET PRICE TO $31 FROM $30
Reuters · 2h ago
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
TipRanks · 2h ago
Denali Therapeutics Price Target Maintained With a $32.00/Share by BTIG
Dow Jones · 3h ago
BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target
Benzinga · 3h ago
Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs
TipRanks · 14h ago
Denali Therapeutics (DNLI): Reassessing Valuation After $275m Royalty Deal and Hunter Syndrome Launch Progress
Simply Wall St · 17h ago
More
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Webull offers Denali Therapeutics Inc stock information, including NASDAQ: DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNLI stock methods without spending real money on the virtual paper trading platform.